Josanna M Rodriguez-Lopez, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 4 | 2023 | 2599 | 0.690 |
Why?
|
| Exercise Test | 1 | 2023 | 2186 | 0.500 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 2 | 2021 | 141 | 0.290 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 1605 | 0.150 |
Why?
|
| Exercise Tolerance | 1 | 2023 | 846 | 0.150 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2017 | 33 | 0.150 |
Why?
|
| Endarterectomy | 1 | 2017 | 196 | 0.140 |
Why?
|
| Learning Curve | 1 | 2017 | 232 | 0.130 |
Why?
|
| Nitric Oxide | 2 | 2022 | 2146 | 0.130 |
Why?
|
| Dyspnea | 1 | 2023 | 1352 | 0.120 |
Why?
|
| Respiration | 1 | 2021 | 1661 | 0.120 |
Why?
|
| Education, Medical, Continuing | 1 | 2017 | 829 | 0.100 |
Why?
|
| Endocytosis | 1 | 2016 | 955 | 0.090 |
Why?
|
| Perfusion Imaging | 2 | 2022 | 195 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2018 | 9384 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 1506 | 0.080 |
Why?
|
| Acute Disease | 1 | 2018 | 7241 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2019 | 2521 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2018 | 3467 | 0.070 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 4427 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2021 | 3238 | 0.050 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 1899 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 13489 | 0.050 |
Why?
|
| Hospitalization | 1 | 2021 | 10840 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 5366 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 1169 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 425 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 10757 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 65364 | 0.040 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2020 | 208 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2019 | 570 | 0.030 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2016 | 105 | 0.030 |
Why?
|
| Inflammation | 1 | 2016 | 10871 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 1736 | 0.030 |
Why?
|
| Humans | 10 | 2023 | 767991 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2018 | 662 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 2227 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2018 | 1531 | 0.030 |
Why?
|
| Biological Transport | 1 | 2016 | 2085 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2017 | 1480 | 0.020 |
Why?
|
| Oxygen | 1 | 2022 | 4269 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2021 | 4194 | 0.020 |
Why?
|
| Emergency Medicine | 1 | 2019 | 1222 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 1946 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 2055 | 0.020 |
Why?
|
| Cholesterol | 1 | 2016 | 2914 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2019 | 81746 | 0.020 |
Why?
|
| Length of Stay | 1 | 2017 | 6495 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 14783 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 10094 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3251 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2022 | 41749 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2016 | 7876 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2016 | 22287 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2019 | 24314 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 39345 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20757 | 0.010 |
Why?
|
| Male | 3 | 2019 | 364641 | 0.010 |
Why?
|
| Aged | 2 | 2018 | 171446 | 0.010 |
Why?
|
| Female | 3 | 2019 | 397113 | 0.010 |
Why?
|
| Middle Aged | 2 | 2018 | 223422 | 0.010 |
Why?
|
| Adult | 1 | 2017 | 223583 | 0.000 |
Why?
|